inmagene-launched-us-subsidiary;-dr-jean-louis-saillot-joined-the-company.

Inmagene launched U.S. subsidiary; Dr. Jean-Louis Saillot joined the company.

 

Inmagene Biopharmaceuticals (“Inmagene”), a leading biotech company focused on immunology-related therapeutic areas, today announced the launch of its wholly-owned subsidiary in San Diego. Jean-Louis Saillot, MD has joined the company as Chief Development Officer (CDO) to oversee its global product development and clinical trial activities.

“Inmagene U.S. is integral to our global innovation platform,” said Dr. Jonathan Wang, Inmagene’s Chairman and CEO. “Dr.’s Saillot has brought us over three decades of clinical research and development experience from multinational pharmaceutical companies, such as BMS/Celgene, Merck/Schering-Plough, and SmithKline Beecham. His experience in leading multiple successful NDAs/MMAs will greatly boost Inmagene’s global drug development capabilities, and enable us to introduce well-needed medicines to the large patient populations in Asia.”

“I am excited to join Inmagene, a truly innovative company developing novel drug candidates for patients suffering from immune diseases,” said Dr. Saillot. “We will integrate world-class drug development knowledge and global market intelligence to guide cost-efficient innovation in Asia, and deliver drug candidates with first-in-class or best-in-class potential to treat patients worldwide.”

Leave a Reply

Your email address will not be published. Required fields are marked *